Matches in Nanopublications for { ?s ?p "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1242089.RAa81HHVSE3NZdL1aZz4WFnL_cVLnn_ldPYSyR-adOXOI130_assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1242089.RAa81HHVSE3NZdL1aZz4WFnL_cVLnn_ldPYSyR-adOXOI130_provenance.
- NP1242091.RAUnFGYox3oNEMYa2-lZLfjyw8M2CeIAdhoELJ4_4P2ns130_assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1242091.RAUnFGYox3oNEMYa2-lZLfjyw8M2CeIAdhoELJ4_4P2ns130_provenance.
- NP1242092.RATfsMrHJxLKfi2bMZp2QOqqt0i__JAbVjEVw1f5tj1NA130_assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1242092.RATfsMrHJxLKfi2bMZp2QOqqt0i__JAbVjEVw1f5tj1NA130_provenance.
- NP1242093.RAH6_mX4dLVYXnVreYU5NaUg0pIzt8_P_DePB0154vOQ4130_assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1242093.RAH6_mX4dLVYXnVreYU5NaUg0pIzt8_P_DePB0154vOQ4130_provenance.
- NP1242090.RA_g0etSULautbwWyi2YmDUipBPQT6Uv1pujvza-v2nak130_assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1242090.RA_g0etSULautbwWyi2YmDUipBPQT6Uv1pujvza-v2nak130_provenance.
- NP1242094.RA6zMrv6RxW0-AECXqPK_p9KNoO2gLMJRtrQbCLdXGBpQ130_assertion description "[Vasoactive intestinal peptide (VIP) exerts similar effects in prostate cancer models involving increased expression of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) which are related to NF-?B transactivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1242094.RA6zMrv6RxW0-AECXqPK_p9KNoO2gLMJRtrQbCLdXGBpQ130_provenance.